NSE: JBCHEPHARM | BSE: 506943

Expensive Performer

Download real time

1650.30 20.30 (1.25%)

52W Low on Mar 13, 2025

123.3K NSE+BSE Volume

NSE 21 Mar, 2025 3:31 PM (IST)

25,691.4

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

J B Chemicals & Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for JBCHEPHARM, BSE:506943 J B Chemicals & Pharmaceuticals Ltd.

J B Chemicals & Pharmaceuticals Ltd.

10 Feb 2023

1650.30

1.25%

J B CHEMICALS & PHAR

Buy: J B Chemicals & Pharmaceut...

Prabhudas Lilladhar

J B Chemicals & Pharmaceuticals Ltd. is trading above its 30 day SMA of 1613.4

J B Chemicals & Pharmaceuticals Ltd.

10 Feb 2023

1650.30

1.25%

In-line performance

Accumulate: J B Chemicals & Pharmaceut...

Target

ICICI Securities Limited

JB Chemicals & Pharmaceuticals (JBCPL) Q3FY23 performance was broadly in line with our estimates, driven by robust growth across the segments. Consolidated revenue grew 32% YoY to Rs7.9bn (I-Sec: 7.7bn) driven by acquisitions in India.

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1674.3

J B Chemicals & Pharmaceuticals Ltd.

15 Nov 2022

1650.30

1.25%

J B CHEMICALS & PHAR

Buy: J B Chemicals & Pharmaceut...

Target

Prabhudas Lilladhar

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1674.3

J B Chemicals & Pharmaceuticals Ltd.

15 Nov 2022

1650.30

1.25%

Consistent performance

Accumulate: J B Chemicals & Pharmaceut...

Target

ICICI Securities Limited

JB Chemicals & Pharmaceuticals (JBCPL) has reported a strong Q2FY23 performance, broadly in line with our estimates, driven by robust growth in both domestic and CMO segments.

J B Chemicals & Phar.. has an average target of 1937.50 from 3 brokers.

J B Chemicals & Pharmaceuticals Ltd.

08 Aug 2022

1650.30

1.25%

Strong performance

Accumulate: J B Chemicals & Pharmaceut...

Recommendation Target

ICICI Securities Limited

JB Chemicals & Pharmaceuticals (JBCPL) has reported a strong Q1FY23 performance, well ahead of our estimates, driven by robust growth in both domestic and CMO segments.

J B Chemicals & Phar.. has an average target of 1937.50 from 3 brokers.

J B Chemicals & Pharmaceuticals Ltd.

19 Jul 2022

1650.30

1.25%

J B CHEMICALS & PHAR

Buy: J B Chemicals & Pharmaceut...

Prabhudas Lilladhar

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

17 Feb 2022

1650.30

1.25%

Continuously outpacing domestic growth

Buy: J B Chemicals & Pharmaceut...

Target

ICICI Securities Limited

JB Chemicals & Pharmaceuticals’ (JBCPL) Q3FY22 performance was better than our estimates on operational fronts. Excluding revenue deferred to Q3FY21 from Q2FY21, consolidated revenue grew 23% YoY to Rs6bn (I-Sec est: 5.8bn). EBITDA margin stood at 21.3%, higher than our estimate of 19.8%.

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

15 Nov 2021

1650.30

1.25%

Industry beating growth in India drives Q2

Buy: J B Chemicals & Pharmaceut...

ICICI Securities Limited

JB Chemicals & Pharmaceuticals’ (JBCPL) Q2FY22 performance was better than estimates driven by strong growth in India business. EBITDA margin was lower than estimates owing to ESOPs charge. Consolidated revenue grew 33.7% YoY to Rs5.9bn and EBITDA margin dropped 340bps to 21.4%.

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1674.3

J B Chemicals & Pharmaceuticals Ltd.

22 Jun 2021

1650.30

1.25%

J B Chemicals & Pharmaceuticals Ltd

Buy: J B Chemicals & Pharmaceut...

Monarch Networth Capital Limited

J.B. Chemicals & Pharmaceuticals Ltd (JBCP) is one of the fastest growing company in the IPM on the back of its brand and therapy focused strategy. Its strong domestic franchisee (>85% sales from 5 mega brands: Cilacar & Nicardia in Cardiac and Metrogyl & Rantac in Gastro-Intestinal) enjoy enormous brand equity which allows them to earn >35% EBITDA margins. While unwinding of erst-while promoter's transactions provide a permanent shift in base, EBITDA margins likely to be supported at the current levels on account to productivity improvements and renewed focus on CMO, US generics and Russia business. We valued JBCP using SOTP based methodology; valuing Domestic franchisee at 7x FY23E EV/Sales and Exports business at 4x FY23E EV/Sales given their inherent quality. We thus initiate coverage on JBCP with BUY rating and target price of INR 2,000 which is ~33% upside on CMP. At our target price, JBCP is available at 26x FY23E PER; on the CMP JBCP trades at 20x FY23E PER....

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1674.3

J B Chemicals & Pharmaceuticals Ltd.

08 Mar 2021

1650.30

1.25%

JB Chemicals and Pharma - Chasing and delivering growth

J B Chemicals & Pharmaceut...

Monarch Networth Capital Limited

Company has been ranked 28th in the IPM, has increased its position by 4 ranks in the last 12 months JB Domestic branded generic growth has outpaced the market by ~500bp/yr...

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

No results found

Is J B Chemicals & Pharmaceuticals Ltd. worth buying?

193 Votes:

Buy 78.24%

Sell 11.4%

Hold 10.36%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Results Update SEE REPORTS >

pdf